Introduction: Nonsmall cell lung cancer accounts for approximately 80% of all lung cancers, and approximately 75% of cases are diagnosed in the middle and late stages of disease. Unfortunately, limited treatment does not improve the prognosis of advanced disease. Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) represent a new treatment paradigm for nonsmall cell lung cancer. Nevertheless, the immune-related adverse events (irAEs) associated with PD-1 and PD-L1 inhibitors are unique, and early recognition and treatment of these events are essential.
Introduction
Lung cancer remains a leading cause of cancer-related mortality, [1] with nonsmall cell lung cancer (NSCLC) accounting for 80% to 85% of all cases of lung cancer. [2] Based on its pathology, NSCLC can be further subdivided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Compared with small cell lung cancer, the growth of NSCLC cells is slower, and the diffusion occurs relatively late. If diagnosed early, the disease generally has a good prognosis, with surgical resection providing a clinical cure. However, NSCLC is diagnosed as locally advanced or metastatic disease in 70% of patients, [3] leading to an extremely poor 5-year survival rate of 1% to 5% among patients with stage IV NSCLC, a figure that has not changed over the past 25 years. [4] Although first-line systemic treatment for NSCLC consists of surgery followed by cytotoxic chemotherapy and/or radiation therapy, increasing recognition of the critical roles of the immune system in the development and progression of cancer has spurred the development of numerous targeted therapies with significant potential to improve overall survival (OS) in specific NSCLC populations. [5] Currently, it is well established that tumors suppress antitumor immune responses via numerous mechanisms including the production of inhibitory cytokines, recruitment of immunosuppressive immune cells, and upregulation of coinhibitory receptors known as immune checkpoints. [6] In normal physiological environments, the immune checkpoints contribute to inhibiting immune responses against self-antigens to prevent excessive autoimmunity. However, these immune checkpoints are upregulated in many cancers, resulting in cancer-associated immune suppression and immune evasion. [7] PD-1 binds to PD-L1 and decreases effector cytokine production and cytolytic activity, preventing the elimination of cancer. [8] This discovery prompted the development of different monoclonal antibodies targeting either PD-1 or PD-L1 as new treatments for advanced NSCLC.
PD-1 is a type I transmembrane protein receptor expressed on the surface of numerous immune cells such as macrophages, dendritic cells, T-cells, B-cells, and natural killer cells. [7, 9] PD-L1 and PD-L2 both act on PD-1. [10, 11] However, the main function of T-cell regulation within the tumor microenvironment depends on PD-L1, which is expressed on the same cells that express PD-1. In addition, some cancer cells also express PD-L1, [12] and approximately 60% of NSCLCs are PD-L1-positive. [13] Blockade of the PD-1 pathway is believed to increase the anti-tumor immune function of T-cells, enhance natural killer cell activity, and promote antibody production in PD-1-positive B cells. [7, 9] Currently, pembrolizumab and nivolumab, which target PD-1 receptors, have been approved for the first-and second-line treatment of NSCLC, respectively. [5, 14, 15] Other PD-1/PD-L1 inhibitors are in various stages of clinical development. The induction of a tolerance break against the tumor via PD-1/PD-L1 blockade can lead to immune dysregulation, namely immunerelated adverse events (irAEs), which clinically manifest as symptoms including dermatologic, gastrointestinal, hepatic, endocrine, and pulmonary events. [16] In addition to these unique AEs, treatment-related adverse events (trAEs) include fatigue, anorexia, nausea, and diarrhoea. [5, 14, [17] [18] [19] [20] [21] As these treatment-related symptoms affect patients' quality of life, sufficient knowledge, and appropriate management of these events are important. [22, 23] Our study will assess the incidence and nature of irAEs in the oncologic treatment of NSCLC using available anti-PD-1 or anti-PD-L1 antibodies through a systematic review and meta-analysis of the qualifying literature.
Objective
A systematic review and meta-analysis will be performed to clarify the profile of irAEs associated with PD-1 and PD-L1 inhibitors in the treatment of NSCLCs in a systematized manner and summarize the differences in the adverse effects associated with different inhibitors compared with conventional chemotherapy and radiotherapy, including whether these events are dose-dependent.
Primary objective
To describe the profile of irAEs associated with PD-1 and PD-L1 inhibitors in the treatment of NSCLCs in a systematized manner.
Secondary objectives
To compare the irAEs associated with PD-1 and PD-L1 inhibitors with those associated with conventional chemotherapy and radiotherapy. To compare the trAEs associated with PD-1 and PD-L1 inhibitors with those associated with conventional chemotherapy and radiotherapy. To determine whether the severity and frequency of irAEs associated with PD-1 and PD-L1 inhibitors are dose-dependent. To assess whether the profile of irAEs differs among different PD-1 and PD-L1 inhibitors.
Methods
3.1. Eligibility criteria 3.1.1. Types of participants. The included participants will be adults who were diagnosed with NSCLC and treated with anti-PD-1 or anti-PD-L1 antibodies. Previous oncologic therapy will not preclude study inclusion, but anti-PD-1 or anti-PD-L1 antibodies must be administered separately without combination therapy. Eligible comparison treatments will be chemotherapy, radiation therapy, targeted therapy, immunity therapy, and multiple combination therapies. There will be no restrictions regarding sex, race/ethnicity, education, and economic status.
3.1.2. Types of studies. This study will include randomized controlled trials (RCTs), case series, and case reports published in peer-reviewed journals without language or time restrictions. Cohort studies, case-control studies, cross-sectional studies, postmarketing vaccine surveillance studies, and other nonrandomized studies will be excluded.
Exclusion criteria.
Review articles, non-RCTs, or RCTs combining anti-PD-1 antibodies or anti-PD-L1 antibodies with other treatment modalities will be excluded.
Outcomes
The incidence evaluation will be based on the number of irAEs and their grades [1-5, recorded according to Version 2, 3, or 4 of the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute]. Grades ≥ 3 will be considered high-grade.
Primary outcomes.
The incidences of irAEs and trAEs associated with PD-1 and PD-L1 inhibitors in the treatment of NSCLC. The incidences of irAEs and trAEs associated with conventional chemotherapy and radiotherapy in the treatment of NSCLC. The incidences of organ-specific adverse events (AEs), especially immune-related pneumonia, and deaths related to Sun et 
The incidences of organ-specific AEs, especially immunerelated pneumonia, and deaths related to AEs associated with conventional chemotherapy and radiotherapy in the treatment of NSCLCs.
Secondary outcomes.
Comparison of the incidence of irAEs and trAEs between PD-1 and PD-L1 inhibitors and conventional chemotherapy/radiotherapy.
Comparison of the incidence of organ-specific AEs, especially immune-related pneumonia, and deaths related to AEs between PD-1 and PD-L1 inhibitors conventional chemotherapy/ radiotherapy.
Information sources
A systematic literature search through December 2016 will be performed using EMBASE, MEDLINE via PubMed, and the Cochrane Central Register of Controlled Trials for relevant articles published in any language.
Search strategy
The relevant searching terms will match Medical Subject Heading terms, and the searches will be repeated immediately before the final analyses to identify additional studies for inclusion. An example of the PubMed search strategy is shown in Table 1 .
3.5. Study records 3.5.1. Data management. An electronic parent folder will be created for this study. The folder will contain several subfolders to incorporate all records retrieved using the following criteria: database of retrieval, the full text of the included studies, the results of risk of bias assessments and subgroup analyses, and full systematic review manuscript drafts. The aforementioned task will be the responsibility of the first author (XYS) in consultation with another author (SYC). The parent folder will be backed up on 2 author's mobile hard drives.
Selection process.
Two authors (XYS and SYC) will screen the search outputs using titles and abstracts to assess whether they meet the inclusion criteria as defined by the protocol and then read the full text of all potentially eligible studies independently for further discrimination of eligible studies. The full text will be obtained through databases or by contacting the corresponding author of the article that will be in the charge of another 2 authors (BF and RR). Discrepancies regarding study inclusion between the 2 authors will be resolved via consensus with the assistance of the senior author.
3.5.3. Data collection process and data items. Data will be extracted from the included studies by 2 authors (XYS and SYC) independently and recorded on a predesigned extraction list. The following data will be captured in the systematic review and meta-analysis: Terminology Criteria for Adverse Events of the National Cancer Institute 4. IrAEs/trAEs: type, frequency of any grade, frequency of severe grade, and the median time to onset. 5. Frequency of organ-specific AEs, especially immune-related pneumonia, and the incidence of death related to irAEs.
Assessment of risk of bias
The Cochrane Collaboration's 'risk of bias' tool will be used to assess the risk of bias and evaluate the quality of articles included in the systematic review and meta-analysis, [24] and to address selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases. Two authors will independently conduct this quality assessment, with agreement reached via consensus.
Data synthesis
All meta-analyses will be performed using RevMan 5.2 software. Statistical heterogeneity between the selected studies will be assessed using the x 2 test and I-squared statistic. Subgroup analyses will be performed to explore potential causes of heterogeneity. The relative risk will be calculated for dichotomous data with 95% confidence intervals for all analyses.
3.7.1. Subgroup analysis. If sufficient data can be obtained, then subgroup analyses will be conducted for high-, median-, and low-dose cohorts. Other variables that will be considered for subgroup analysis include the type (anti-PD-1 vs anti-PD-L1) and brand of antibody drugs.
3.7.2. Sensitivity analysis. Sensitivity analysis will be performed to confirm whether the results are robust and credible by excluding highly biased studies.
Reporting of the review
The preferred reporting items for systematic reviews and metaanalyses (PRISMA) statement will be followed until the findings of the systematic review and meta-analysis are reported. The identification and selection of studies for inclusion will be summarized using flow diagrams. Characteristics of the studies Table 1 Search strategy for PubMed.
Query
Search term and the incidence of global adverse events associated with anti-PD-1 and anti-PD-L1 therapies will be presented in tables. The quality assessment and summary of other adverse events will be described in the text.
#1

Discussion
To our knowledge, this will be the first systematic review and meta-analysis reporting all published irAEs related to PD-1 and PD-L1 inhibitors in the treatment of NSCLC. Currently, the study of anti-PD-1 and anti-PD-L1 transitions from basic research to clinical research; however, safety concerns represent the primary limitation of the clinical application stage. Using all RCTs, case series, and case reports included in the pooled analysis, we will determine the incidences of all-grade and high-grade irAEs, which may highlight the high risk of irAEs associated with anti-PD-1 and anti-PD-L1 drugs in the treatment of NSCLC. PD-1 and PD-L1 inhibitors are demanded because of the poor prognosis of NSCLC despite their potentially high risk of irAEs. Several antibodies have been approved for the second-line and higher treatment of NSCLC, and they are associated with significant improvements in progression-free survival and OS versus conventional chemotherapy [15] ; thus, security details need to be observed and monitored in the clinical practice. This systematic review will be conducted to clarify essential details associated with anti-PD-1 and anti-PD-L1 drugs in the treatment of NSCLC and the findings of the review may facilitate early prediction, comprehensive observation, and prompt management of irAEs in addition to better patient compliance.
We will report the review results according to PRISMA guidelines and search, screen, assess, and extract valuable data from several databases comprehensively and meticulously as previously mentioned. As trAEs may be reported instead of irAEs in studies of anti-PD-1 and anti-PD-L1 drugs in patients with NSCLC, it may be impossible to conduct the review as described in this article. This consideration will be addressed in the discussion of published studies, and the study results will be disseminated in peer-reviewed journals.
